Aristo Pharma Nordic ApS: Financial statements 2024
CVR: 32328768
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Aristo Pharma Nordic ApS (CVR 32328768) has filed annual accounts for 2024. In 2024, the company reported revenue of EUR 528,984 and a net result of EUR 25,190 compared with EUR 25,848 the year before. The profit margin was 4.8%. Equity in the 2024 report amounted to EUR 163,285. The solvency ratio was 6.6%. The company had 3 employees in the financial year.
- Revenue
- EUR 528,984
- Gross Profit
- EUR 363,142
- Profit/Loss
- EUR 25,190
- Equity
- EUR 163,285
- Total Assets
- EUR 2,465,669
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 529K EUR | 363K EUR | 25K EUR | 163K EUR | 3 |
| 2023 | - | 327K EUR | 26K EUR | 138K EUR | 3 |
| 2022 | - | 717K EUR | 52K EUR | 112K EUR | 5 |
| 2021 | - | 789K EUR | 45K EUR | 61K EUR | 7 |
| 2020 | - | 805K EUR | 62K EUR | -1.3M EUR | 7 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Aristo Pharma Nordic ApS has published its annual report for 2023. Gross profit came to DKK 326,645, and the net result was DKK 25,848.
As of March 31, 2024, Jannes Paul Beeskow has joined the board of directors of Aristo Pharma Nordic ApS.
As of March 31, 2024, Sascha Rauschke has left the board of directors of Aristo Pharma Nordic ApS.
As of March 31, 2024, John Hudson Kriwet is registered as director of Aristo Pharma Nordic ApS.
As of March 31, 2024, Sascha Rauschke has stepped down as director of Aristo Pharma Nordic ApS.
About Aristo Pharma Nordic ApS
Aristo Pharma Nordic ApS is a Danish company of the type Anpartsselskab based in Skovlunde, founded in 2011. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named AMNEAL NORDIC ApS and COPHARMA ApS. The management consists of John Hudson Kriwet. The board consists of John Hudson Kriwet (chair), Jannes Paul Beeskow and Robert Maciej Szymanski. The company is owned by Aristo Pharma GmbH. The company has 1 employee (2026). In 2025, the company reported revenue of EUR 453,392 and a net result of EUR 21,589 compared with EUR 25,190 the year before. Equity in the 2025 report amounted to EUR 184,874.